Filtered By:
Vaccination: Malaria Vaccine

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 69 results found since Jan 2013.

U.S. Scientists Are Starting From Ground Zero With The Zika Vaccine
As the research community gears up to address Zika virus, one common question has been why, if we’ve known about Zika since 1947, are we only starting these efforts in 2016? As Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, admitted, the disease is uncharted territory. "We, prior to this time, have really not spent anything on Zika,” he said during a press conference Thursday. Currently, there is no cure and no vaccine for the disease, and diagnosing the disease takes up to two weeks in specialized labs.  To ramp up research on the Zika virus threat, the...
Source: Healthy Living - The Huffington Post - January 29, 2016 Category: Consumer Health News Source Type: news

NIH-funded study reveals why malaria vaccine only partially protected children, infants
(NIH/National Institute of Allergy and Infectious Diseases) Using new, highly sensitive genomic sequencing technology, an international team of researchers has found new biological evidence to help explain why the malaria vaccine candidate RTS,S/AS01 (called RTS,S) provided only moderate protection among vaccinated children during clinical testing. The researchers, funded in part by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, found that genetic variability in the surface protein targeted by the RTS,S vaccine likely played a significant role.
Source: EurekAlert! - Infectious and Emerging Diseases - October 22, 2015 Category: Infectious Diseases Source Type: news

The RTS,S/AS01 vaccine continues to show modest protection against malaria in African infants and children
This report provides final follow-up data for a large phase III trial conducted at 11 sites in sub-Saharan Africa. It...
Source: Evidence-Based Medicine - September 24, 2015 Category: Internal Medicine Authors: Rosenthal, P. J. Tags: Clinical trials (epidemiology), Immunology (including allergy), Meningitis, Travel medicine, Tropical medicine (infectious diseases), Vaccination / immunisation, Infection (neurology) Therapeutics/Prevention Source Type: research

Sean Parker Just Gave $600 Million To Help Solve The World's Biggest Problems
While it’s not unusual for tech billionaires to commit to philanthropic efforts these days, it would be tricky to find an analog for the approach being taken by former Facebook President Sean Parker with his newly announced foundation. That’s because Parker is aiming to bring a “go big or go home” Silicon Valley-informed approach to his San Francisco-based Parker Foundation, which has been established through a $600 million gift from the Napster cofounder and Spotify board member. The foundation will focus on three core areas where Parker thinks real progress can be made: civic engagement, global public health and ...
Source: Healthy Living - The Huffington Post - June 24, 2015 Category: Consumer Health News Source Type: news

Exploring immunological mechanisms of the whole sporozoite vaccination against P. falciparum malaria.
This report summarizes the discussions and major conclusions from the workshop participants. PMID: 25917675 [PubMed - as supplied by publisher]
Source: Vaccine - April 24, 2015 Category: Allergy & Immunology Authors: Mo AX, Pesce J, Hall BF Tags: Vaccine Source Type: research

Phase 3 trial with the RTS,S/AS01 malaria vaccine shows protection against clinical and severe malaria in infants and children in Africa
Commentary on: RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014;11:e1001685. Context There is currently no licensed malaria vaccine. Protection against malaria is dependent on use of insecticide-treated nets, other vector control measures and drug treatment. These have reduced the burden of disease over the past decade, but it remains unacceptably high.1 Malaria transmission is heterogeneous and there are particular challenges presented by h...
Source: Evidence-Based Medicine - January 21, 2015 Category: Internal Medicine Authors: Targett, G. Tags: Clinical trials (epidemiology), Immunology (including allergy), Travel medicine, Tropical medicine (infectious diseases), Vaccination / immunisation Therapeutics/Prevention Source Type: research

MPLA shows attenuated pro‐inflammatory properties and diminished capacity to activate mast cells in comparison to LPS
ConclusionsCompared to LPS, MPLA induced a qualitatively similar, but less potent pro‐inflammatory immune response, but was unable to activate human or mouse MCs.This article is protected by copyright. All rights reserved.
Source: Allergy - January 1, 2015 Category: Allergy & Immunology Authors: Stefan Schülke, Adam Flaczyk, Lothar Vogel, Nicolas Gaudenzio, Isabelle Angers, Bettina Löschner, Sonja Wolfheimer, Ingo Spreitzer, Salman Qureshi, Mindy Tsai, Stephen Galli, Stefan Vieths, Stephan Scheurer Tags: Original Article Source Type: research

Title: The WASH Approach: Fighting Waterborne Disease in Emergency Situations
Refugees collect water from a public tap stand in an Adjumani settlement. © Wendee Nicole Rhino Camp, Arua District. Refugees in Uganda live on land donated by Ugandan nationals. Refugee families are given plots on which they can build temporary shelters and grow crops.© Wendee Nicole Oxfam staff members Tim Sutton (left) and Pius Nzuki Kitonyi (right) with the soon-to-be-repaired water pump in Adjumani. In disaster-affected situations, Oxfam takes a lead in delivering WASH-related services.© Wendee Nicole Hand-operated water pumps are a reliable source of pre...
Source: EHP Research - December 31, 2014 Category: Environmental Health Authors: Web Admin Tags: Featured Focus News Community Health Disaster Response Drinking Water Quality Infectious Disease Infrastructure International Environmental Health Microbial Agents Sanitation Warfare and Aftermath Water Pollution Source Type: research

Evaluation of the adjuvant activity of propranolol, a Beta-adrenergic receptor antagonist, on efficacy of a malaria vaccine model in BALB/c mice.
In this study PRP was used as an adjuvant in combination with Plasmodium berghei (P. berghei) whole blood stage (PWBS) antigens. BALB/c mice were immunized three times with a 2-week interval, either PWBS vaccine alone or in combination with the adjuvant alum or propranolol. The control group received phosphate buffered saline. Evaluation of the cellular and humoral immunity was performed by measurement of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, lymphocyte proliferation, total IgG and IgG2a in the control and immunized groups. Furthermore, Clinical evaluations were carried out by analyze survival rate and paras...
Source: Iranian Journal of Allergy, Asthma and Immunology - August 31, 2014 Category: Allergy & Immunology Authors: Shahabi S, Mohammadzadeh Hajipirloo H, Keramati A, Hazrati Tappeh K, Bozorgomid A Tags: Iran J Allergy Asthma Immunol Source Type: research

Vaccine made from complex of two malaria proteins protects mice from lethal infection
(NIH/National Institute of Allergy and Infectious Diseases) An experimental vaccine designed to spur production of antibodies against a key malaria parasite protein, AMA1, was developed more than decade ago by scientists from NIAID, part of NIH. It showed promise in test-tube and animal experiments and in early-stage clinical trials, but returned disappointing results in recent human trials conducted in malaria-endemic countries.
Source: EurekAlert! - Infectious and Emerging Diseases - June 23, 2014 Category: Infectious Diseases Source Type: news

AMA1-RON2 Complex-based Vaccine Against Malaria
This technology relates to a malaria vaccine composed of a protein complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 (RON2) with an adjuvant. AMA1 is a crucial component of the Plasmodium invasion machinery and is a leading candidate for antimalarial vaccine development. AMA1-based vaccines have shown ability to block red cell invasion in in vitro assays, but protection has so far not translated to in vivo human infections. NIAID investigators have demonstrated that interaction between AMA1 and RON2 (or peptide thereof) is essential for malaria parasites to successfully enter human red blood cells (RBCs...
Source: NIH OTT Licensing Opportunities - June 18, 2014 Category: Research Authors: admin Source Type: research

Immune activation alters cellular and humoral responses to yellow fever 17D vaccine
Conclusion. Together, these results demonstrate that an activated immune microenvironment prior to vaccination impedes efficacy of the YF-17D vaccine in an African cohort and suggest that vaccine regimens may need to be boosted in African populations to achieve efficient immunity.Trial registration. Registration is not required for observational studies.Funding. This study was funded by Canada’s Global Health Research Initiative, Defense Threat Reduction Agency, National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, and United States Agency for International Development.
Source: Journal of Clinical Investigation - June 10, 2014 Category: Biomedical Science Authors: Enoch Muyanja, Aloysius Ssemaganda, Pearline NGauv, Rafael Cubas, Helene Perrin, Divya Srinivasan, Glenda Canderan, Benton Lawson, Jakub Kopycinski, Amanda S. Graham, Dawne K. Rowe, Michaela J. Smith, Sharon Isern, Scott Michael, Guido Silvestri, Thomas H Source Type: research

Fresh hope in hunt for malaria vaccine
Conclusion Using a combination of laboratory protein experiments, mouse infection studies, and human susceptibility cohorts, this research developed a new prototype vaccine targeting the PfSEA-1 protein. This approach shows promise in partially reducing malaria infection in mice. The vaccine appeared to mimic the natural resistance to malaria infection found in some children and adolescents living in malaria endemic regions of Tanzania and Kenya. It is important to note that the vaccine was not 100% effective but, if developed successfully, it may still be useful if used in combination with other vaccines. Though this l...
Source: NHS News Feed - May 23, 2014 Category: Consumer Health News Tags: Medication Pregnancy/child Source Type: news